✦ LIBER ✦

Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones

✍ Scribed by Kang, B H; Altieri, D C

Book ID: 109971028
Publisher: Nature Publishing Group
Year: 2009
Tongue: English
Weight: 576 KB
Volume: 28
Category: Article
ISSN: 0950-9232
DOI: 10.1038/onc.2009.227

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Targeting mitochondrial permeability in

Targeting mitochondrial permeability in cancer drug development

✍ Michael V. Berridge; Patries M. Herst; Alfons Lawen 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 360 KB

## Abstract The past decade has seen the emergence of a new mechanistic paradigm of cancer therapeutics. Not only have mitochondria taken centre stage as key cellular organelles mediating intrinsic pathways of cell death by apoptosis, but nonapoptotic pathways have also been shown to involve mitoch

Drug discovery approaches targeting the

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

✍ Garcia-Echeverria, C; Sellers, W R 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 343 KB

Targeted inhibition of mitochondrial Hsp

Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease

✍ Kang, B H; Tavecchio, M; Goel, H L; Hsieh, C-C; Garlick, D S; Raskett, C M; Lian 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 485 KB

Targeting EGFR and HER-2 Receptor Tyrosi

Targeting EGFR and HER-2 Receptor Tyrosine Kinases for Cancer Drug Discovery and Development

✍ Shantaram Kamath; John K. Buolamwini 📂 Article 📅 2006 🏛 John Wiley and Sons ⚖ 8 KB

Targeting EGFR and HER-2 receptor tyrosi

Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development

✍ Shantaram Kamath; John K. Buolamwini 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 472 KB

Conventional anticancer therapy using cytotoxic drugs lacks selectivity and is prone to toxicity and drug resistance. Anticancer therapies targeting aberrant growth factor receptor signaling are gaining interest. The erbB receptor family belongs to the type I, the receptor tyrosine kinases class, an